The first stop for professional medicines advice

Biosimilars

24 results

Applied filters

Preparing to use tocilizumab biosimilar

5 March 2024Introducing biosimilar tocilizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.

Preparing to use natalizumab biosimilar

6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.

Good governance when implementing natalizumab biosimilar

6 February 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.

The licence and supporting evidence for natalizumab biosimilar

6 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.

Preparing to use ranibizumab biosimilar

29 June 2022Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team

Good governance when implementing ranibizumab biosimilar

29 June 2022Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance

The licence and supporting evidence for ranibizumab biosimilars

29 June 2022Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence

Understanding biological and biosimilar medicines

29 June 2022Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions
Registration required

Summary of biopharmaceutical stability data reviewed and available extended shelf-life data

4 June 2021The stability of several aseptically compounded ready to administer presentations of monoclonal antibody products and other biopharmaceuticals is presented.

Biosimilars

Regularly updated material to support the introduction of adalimumab, eculizumab, natalizumab, ranibizumab, tocilizumab and ustekinumab biosimilars.
admin